ABSTRACT. The purpose of this study was to determine whether treatment with L-carnitine or acetyl-L-carnitine enhances the turnover of lipid or branched-chain amino acid oxidation in patients with inborn errors of metabolism. Increasing i.v. doses of L-carnitine and acetyl-L-carnitine were given to one patient with medium-chain acyl-CoA dehydrogenase deficiency and to another with isovaleric acidemia. Both patients were in stable condition and receiving oral L-carnitine supplements. The excretion of carnitine and disease-specific metabolites was measured. The incorporation of L-carnitine in the intracellular pool was demonstrated using stable isotopes and mass spectrometry.
ABSTRACT. The purpose of this study was to determine whether treatment with L-carnitine or acetyl-L-carnitine enhances the turnover of lipid or branched-chain amino acid oxidation in patients with inborn errors of metabolism. Increasing i.v. doses of L-carnitine and acetyl-L-carnitine were given to one patient with medium-chain acyl-CoA dehydrogenase deficiency and to another with isovaleric acidemia. Both patients were in stable condition and receiving oral L-carnitine supplements. The excretion of carnitine and disease-specific metabolites was measured. The incorporation of L-carnitine in the intracellular pool was demonstrated using stable isotopes and mass spectrometry. Increasing doses of either i.v. L-carnitine or acetyl-L-carnitine did not stimulate the excretion of octanoylcarnitine in the patient with medium-chain acyl-CoA dehydrogenase deficiency, nor did it raise the plasma levels of either cis4decenoate or octanoylcarnitine. Similarly, increasing doses of either i.v. L-carnitine or acetyl-L-carnitine did not enhance the excretion of isovalerylcarnitine in a patient with isovaleric acidemia. The excretion of isovalerylglycine actually decreased. We conclude that there was no evidence of enhanced fatty acid &oxidation or enhanced branchedchain amino acid oxidation in vivo by the administration of high doses of ~-carnitine or acetyl-L-carnitine in these two patients. Because only one individual with each disorder was studied, the data are only indicative and may not necessarily be representative of all individuals with these disorders. Definite settlement of this issue will require further studies in additional subjects. (Pediatr Res 35: 96-101,1994) Abbreviations MCAD, medium-chain acyl-CoA dehydrogenase IVA, isovaleric acidemia GC/MS, gas chromatography/mass spectrometry carnitine supplementation is to correct an existing deficiency ( 1), restore the mitochondrial acyl-CoA/free CoA ratio, and provide an efficient conjugate for the excretion of accumulating toxic intermediates (2) .
MCAD deficiency is the most common inherited disorder of fatty acid metabolism. Plasma and tissue free carnitine concentrations are reduced in this disorder (3), and there is increased excretion of the medium-chain acylcarnitines (4) . Oral L-carnitine supplementation can normalize the plasma carnitine level and increases the excretion of octanoylcarnitine in comparison with the excretion before treatment (4) (5) (6) . This enhanced excretion is further increased during acute episodes of illness (7) .
The safety of L-carnitine supplementation in patients with MCAD deficiency has been questioned. In carnitine-deficient tissues, carnitine may be rate limiting and addition of L-carnitine could enhance fatty acid oxidation (8) . It has been suggested that in MCAD deficiency, L-carnitine might increase mitochondrial uptake of fatty acids and thus stimulate p-oxidation, leading to increased production of toxic intermediates (9-1 1).
IVA is caused by a defect in the metabolism of the amino acid leucine due to a deficiency in isovaleryl-CoA dehydrogenase. Oral L-carnitine therapy in IVA has resulted in the enhanced excretion of isovalerylcarnitine (1 2, 13). In vitro studies have indicated that L-carnitine can enhance oxidation of the branchedchain amino acids leucine and valine in muscle homogenates (14) . Theoretically, L-carnitine therapy in a patient with IVA could increase the production of isovaleryl-CoA through increased branched-chain amino acid oxidation.
This study was designed to assess the safety of L-carnitine and acetyl-L-carnitine administration to patients with metabolic disorders. Disease-specific metabolites were monitored while increasing i.v. doses of L-carnitine were given to one patient with MCAD deficiency and to another patient with IVA. Acetyl-Lcarnitine was also investigated because it can provide the potential benefit of additional acetyl-CoA groups to the mitochondria (15 Isotope labeling studies. To study the metabolic fate of the administered L-carnitine and acetyl-L-carnitine, two separate stable isotope-labeled studies were done. These studies involved single bolus i. Before these studies were done, both patients had been on oral L-carnitine supplementation (100 mg/kg/d). A washout period of 1 d on baseline oral L-carnitine therapy was scheduled between studies of L-carnitine and acetyl-L-carnitine administration. Intravenous doses were given as a slow push over 3 to 5 min. Daily timed 24-h urine collections were obtained for the measurement of free L-carnitine, acetyl-L-carnitine, and the appropriate acylcarnitine species (octanoylcarnitine in patient 1 and isovalerylcarnitine in patient 2). Isovalerylglycine and benzoylglycine were measured in the urine collections of patient 2. Blood samples were obtained for cis-4-decenoate and octanoylcarnitine levels in patient 1.
Daily oral intake was monitored to assure a steady intake of relevant nutrients. Blood samples were analyzed for routine hematologic studies, electrolytes, transaminases, calcium, phosphorus, and alkaline phosphatases, ammonia, and lactate.
L-Carnitine and acetyl-L-carnitine were a gift from Sigma Tau Pharmaceuticals (Rome, Italy). Octanoyl-DL-carnitine was purchased from Sigma Chemical Co. . Chemical and isotopic purity of these standards was confirmed by mass spectrometry and nuclear magnetic resonance spectrometry. N-methyl-N-trimethylsilyl-trifluoroacetamide was purchased from Pierce (Rockford, IL).
Twenty-four-h urine collections were analyzed for free Lcarnitine (22) , acetyl-L-carnitine, and appropriate acylcarnitines (either octanoylcarnitine or isovalerylcarnitine) by fast atom bombardment tandem mass spectrometry with isotope-labeled internal standards using previously published methods (23) . Plasma carnitine levels were measured by radioenzymatic assay (24) . Plasma octanoylcarnitine was measured by fast atom bombardment tandem mass spectrometry as previously described (25) . Standard addition of octanoyl-D,L-carnitine to control plasma samples over a concentration range of 0.2 to 8 nmol/mL (r = 0.99, n = 9) produced a linear calibration and the coefficient of variation for the overall assay was 4.4% (n = 7). Cis-4-decenoate was measured by GC/MS in extracts of 50 pL of plasma spotted on filter paper as previously described (26, 27) . Isovalerylglycine was quantified by GC/MS using selected ion monitoring, as follows: 100 pL of urine plus 50 pg of [2H~-methyl]isovalery1glycine was diluted to 1 mL and extracted three times with ethyl acetate after acidification with HCl and saturation with NaCl. After drying under a gentle stream of nitrogen, the sample was derivatized with 75 pL of N-methyl-Ntrimethylsilyl-trifluoroacetamide at 80°C for 3 h. Hematologic studies and analysis of electrolytes, liver function tests, ammonia, and lactate were performed by the Duke Hospital Laboratories by standard procedures.
Ethics. The study was approved by the Duke Institutional Review Board (IRB 124-93-IR10). The patients were admitted to the clinical research unit and informed consent was obtained from a parent.
RESULTS
Baseline plasma carnitine and acylcarnitine levels in the patient with MCAD deficiency (patient I) were 42 pM (free carnitine), 8 pM (short-chain acylcarnitine), and 4 pM (long-chain acylcarnitine). In patient 2, with IVA, the corresponding levels were 88 pM, 33 pM, and 4 pM. In patient 1, increasing doses of i.v. L-carnitine above the equivalent oral maintenance level had no perceptible effect on the excretion of octanoylcarnitine or acetylcarnitine but increased the excretion of free carnitine by about 50% of the administered dose (Fig. 1A) . Administration of i.v. acetyl-L-carnitine in increasing doses had no measurable effect on the octanoylcarnitine excretion in this patient (Fig. 1 B) , but the excretion of acetylcarnitine and free carnitine increased. The plasma concentrations of cis-4-decenoate and octanoylcarnitine showed no relationship to the administered doses of either L-carnitine or acetyl-L-carnitine (Table 1) . In the patient with IVA, increasing i.v. doses above maintenance level of either L-carnitine (Fig. 1C) or acetyl-L-carnitine (Fig. 1D) did not stimulate the excretion of isovalerylcarnitine. Isovalerylglycine excretion actually fell during high-dose therapy (Table 2 ). During administration of high doses of L-carnitine, the molar excretion of isovalerylglycine approached the excretion of isovalerylcarnitine (Fig. 1 C, Table 2 ) in this patient, who was not supplemented with glycine; however, at the commonly used oral maintenance dose, the isovalerylglycine concentration was considerably higher than that of isovalerylcarnitine. Benzoylglycine excretion was essentially unaffected by increasing doses of both L-carnitine and acetyl-L-carnitine. sion of stable isotope-labeled L-carnitine and acetyl-L-carnitine. For the patient with MCAD deficiency, the acylcarnitine profiles for the 24-h urine collections before and after the isotope infusion are shown in Figure 2A and B. The incorporation of isotopically labeled carnitine into the acylcarnitines is clearly demonstrated by the appearance of new molecular ion signals with a shift of +3 mass units, corresponding to acetyl-'H3-carnitine (m/z 22 l), he~anoyl-~H3-carnitine (m/z 277), octenoyl-*H3-carnitine (m/z 303), octanoyl-'H3-carnitine (m/z 305), and de~enoyl-~H~-carnitine (m/z 33 1) (Fig. 2B) . The signals for free carnitine and 2 H~ carnitine appear at m/z 176 and 179, respectively. An i.v. bolus of a~etyl-[~H3-rneth~l]~-carnitine given to this patient resulted in the excretion of the same isotopically labeled metabolites (Fig.  2C) .
When the patient with IVA was given an i.v. bolus of [2H,-methyl]carnitine, a new signal in the urine acylcarnitine profile was observed at m/z 263, corresponding to isovaleryl-*H,-carnitine, in addition to that of the unlabeled isovalerylcarnitine (m/z 260) (Fig. 20) .
Both patients remained in stable condition throughout the admission, and hematologic parameters and blood chemistry remained unchanged.
DISCUSSION
This limited study was designed to evaluate the metabolic effect of increasing dosage of L-carnitine and acetyl-L-carnitine in patients with inborn errors of metabolism. We carefully studied two patients in a stable metabolic state, one with MCAD deficiency and one with IVA. In the patient with MCAD deficiency, increasing doses of either L-carnitine or acetyl-L-carnitine did not stimulate the excretion of octanoylcarnitine or increase plasma cis-4-decenoate or plasma octanoylcarnitine. Similarly, in the patient with IVA, increasing doses of L-carnitine or acetyl-L-carnitine did not result in enhanced excretion of isovalerylcarnitine. The excretion of isovalerylglycine actually decreased, and the excretion of benzoylglycine was unaffected.
Intravenous administration of L-carnitine and acetyl-L-carnitine specifically labeled with three deuterium atoms in one of the N-methyl groups resulted in the incorporation of the label into all the acylcarnitines excreted. There was no obvious preference for particular acyl groups as shown by similar enrichment into the different species (Fig. 2) . This provides direct evidence that carnitine administered enters the mitochondria1 pool and rapidly forms acylcarnitines with all available acyl groups, including both the disease-specific and normal species. Acetylcarnitine also exchanges with the acylcarnitine pool.
Previous pharmacokinetic studies have shown that increasing doses of oral L-carnitine do not result in increasingly higher plasma levels, whereas higher plasma levels and higher areas under the curve are achieved by i.v. administration of L-carnitine (19) . This might be explained by the partially camer-mediated, saturable intestinal uptake of carnitine (29-3 l), with incomplete absorption at pharmacologic doses (32) . Furthermore, orally administered acetyl-L-carnitine did not result in the increased excretion of acetylcarnitine, as observed after i.v. administration ( Fig. 1 B and D) . We ascribe this to the substantial deacetylation of acetyl-L-carnitine in the intestinal mucosa, also reported in animal studies (33) . Other workers have observed the same phenomenon (34) . Intravenous acetyl-L-carnitine produced high plasma acetylcarnitine levels (35) . For these reasons, we investigated the increased intake of carnitine and acetylcarnitine by the i.v. route.
In this study, similar excretion of L-carnitine and acylcarnitines was achieved after switching to i.v. administration at 15% of the previously administered oral dose (Fig. 1 ). These data are in 100 VAN 
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agreement with the previously reported estimate of about 15% bioavailability of orally administered carnitine in healthy subjects (1 8, 19 ). The starting point for i.v. dosage was therefore equivalent to the maintenance oral dose.
From the isotope labeling studies, it is clear that L-carnitine and acetylcarnitine administered i.v. enter the mitochondria and equilibrate with the endogenous pool. In the patient with MCAD deficiency, doubling and even quadrupling the i.v. dosage did not affect either the plasma concentrations of octanoylcarnitine and cis-4decenoic acid, or the excretion of octanoylcarnitine. This implies that increased intake of L-carnitine does not of itself stimulate the 8-oxidation of fatty acids in vivo. This is in keeping with the biochemical observation that the rate of fatty acid oxidation is primarily dependent on the concentration of malonyl-CoA rather than the concentration of carnitine (36, 37) .
In the patient with IVA, the fact that isovalerylcarnitine excretion was stable while the excretion of isovalerylglycine, the major metabolite in this disorder (38), decreased by about 50% on the highest dose of i.v. L-carnitine implies that increased intake of camitine does not stimulate the production of isovaleryl-CoA. On the contrary, the accumulation of this toxic intermediate apparently decreases. Inhibition of the glycine-N-acylase by carnitine therapy (39) is an unlikely explanation for this observation, because the excretion of benzoylglycine, whose formation depends on the same enzyme, is unaffected. Furthermore, no concomitant increase was observed in the excretion of 3-hydroxyisovaleric acid, which is also derived from isovaleryl-CoA, according to GC/MS analysis. Because diagnostic metabolites in IVA are primarily derived from endogenous protein turnover (40), we conclude that increasing dosage of i.v. L-carnitine does not enhance branched-chain amino acid catabolism in humans, similar to previously reported observations in normal humans and rats (41-43). Rather, it is possible that higher levels of isovalerylcarnitine in the liver might reduce protein degradation (44, 45). This is one potential explanation for the observation that patients with IVA can be equally cared for with either L-carnitine therapy or with glycine therapy (12, 13, 46, 47) , despite the fact that the excretion of isovalerylcarnitine is less than the excretion of isovalerylglycine.
Enhanced excretion of abnormal acylcarnitines upon supplementation with carnitine in MCAD deficiency and in IVA is well documented (4, 12) . This study indicates that for patients with MCAD deficiency and/or IVA in a stable state, a dose of 620 pmol/kg/d (100 mg/kg/d) oral L-carnitine should provide adequate carnitine availability both to normalize the plasma free carnitine concentration and to provide optimal excretion of the major accumulating abnormal acylcarnitine species. These preliminary data suggest that carnitine administration enhances excretion of accumulated metabolites without further stimulation of their formation. During metabolic crises, patients with MCAD deficiency and IVA rapidly accumulate toxic acyl-CoA intermediates, increasing the need for detoxifiing agents. The increased excretion of the disease-specific acylcarnitines during such episodes (7) illustrates this. This limited study supports the safety of i.v. L-carnitine administration. Because only one individual with each disorder was studied while metabolically stable, the data are only indicative and may not necessarily be representative of all individuals with these disorders. Definite settlement of this issue will require further studies in additional subjects.
